RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas
复制标题
DOI：
10.1007/s00405-004-0835-8
复制
发表时间：
2005-05-01
影响因子：
2.6
通讯作者：
Rothstein, JL
中科院分区：
文献类型：
--
作者：
Nibu, K;Otsuki, N;Rothstein, JL
据报道，通过染色体易位激活 RET 原癌基因是甲状腺乳头状癌所特有的。然而，报道的乳头状癌中 RET/PTC 激活的发生率各不相同，并且乳头状癌中 RET/PTC 重排的临床相关性仍存在争议。为了探讨RET重排在甲状腺乳头状癌发生中的作用，我们通过免疫组织化学技术研究了日本人群各种甲状腺病变中的RET激活和p53过表达。在 40 例乳头状癌、6 例低分化癌、4 例未分化癌、2 例髓样癌、2 例滤泡性癌和 19 例滤泡性腺瘤中研究了 RET 激活和 p53 过表达。在 40 个乳头状癌中有 12 个观察到 RET 激活，而在其他病变中未检测到 RET 免疫反应性。仅在 40 例乳头状癌中的 1 例中观察到 P53 过表达，但在 2 例低分化癌和 4 例未分化癌中观察到 P53 过表达。日本人群中乳头状癌中 RET/PTC 激活的患病率高于之前的报告。免疫组织化学技术被证明是检测甲状腺肿瘤中 RFT/PTC 激活的有用工具。 RET 重排仅限于分化良好的乳头状癌，表明 RET/PTC 阳性乳头状癌不会进展为未分化癌。
The activation of RET proto-oncogene through chromosomal translocation is reported as being unique to papillary thyroid carcinomas. However, the reported prevalence of RET/PTC activation in papillary carcinoma was variable, and the clinical relevance of RET/PTC rearrangements in papillary carcinomas is still controversial. To investigate the roles of RET rearrangement in the carcinogenesis of papillary thyroid carcinoma, we have studied RET activation and p53 overexpression in various thyroid lesions of the Japanese population by immunohistochemical technique. RET activation and p53 overexpression were studied in 40 papillary carcinomas, 6 poorly differentiated carcinomas, 4 undifferentiated carcinomas, 2 medullary carcinomas, 2 follicular carcinomas and 19 follicular adenomas. RET activation was observed in 12 out of 40 papillary carcinomas, while no immunoreactivity of RET was detected in other lesions. P53 overexpression was observed in only 1 of 40 papillary carcinomas, but in 2 poorly differentiated carcinomas and 4 undifferentiated carcinomas. The prevalence of RET/PTC activation in papillary carcinoma among the Japanese population was higher than in previous reports. Immunohistochemical technique is proved to be a useful tool to detect RFT/PTC activation in thyroid tumors. RET rearrangements are restricted to a well-differentiated papillary carcinoma, suggesting that RET/PTC positive papillary carcinomas do not progress to undifferentiated carcinoma.